Company news
Microbot Medical Inc. news in 2025
Microbot Medical Inc.'s news releases, calls and decks from 2025, newest first.
Microbot Medical® Announces Emory University Hospital as the First Hospital in the World to Adopt the New LIBERTY® Endovascular Robotic System
November 26, 2025
Microbot Medical® Commences the Limited Market Release of its LIBERTY® Endovascular Robotic System in the U.S.
November 5, 2025
Microbot Medical® to Commercially Debut the LIBERTY® System at The Symposium on Clinical Interventional Oncology Annual Meeting
October 16, 2025
Microbot Medical® Secures U.S. Based Logistics Partner to Support the Commercialization of Its LIBERTY® Endovascular Robotic System
October 14, 2025
Microbot Medical Announces Final Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds
October 7, 2025
Microbot Medical® Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio
October 1, 2025
Miocrbot Medical® CEO to Discuss Recent FDA Clearance of the LIBERTY® Endovascular Robotic System
September 23, 2025
Microbot Medical Announces First Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds
September 16, 2025
Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for Up to $92.2 Million in Gross Proceeds
September 15, 2025
REMINDER: Microbot Medical to Highlight FDA 510(k) Clearance of the LIBERTY Endovascular Robotic System at the H.C. Wainwright Annual Investor Conference
September 9, 2025
Microbot Medical® Receives FDA 510(k) Clearance for Its LIBERTY® Endovascular Robotic System
September 8, 2025
Microbot Medical® Granted U.S. Patent that Significantly Expands Potential Market Applications
August 20, 2025
DIH Appoints Scott R. Burell to DIH Holding US, Inc. Board of Directors
August 8, 2025
Microbot Medical® Receives Non-Dilutive Grant to Enhance Operational Capabilities
August 5, 2025
Microbot Medical® Expands Commercial Leadership with Appointment of Christina Bailey as VP of Sales
July 22, 2025
Microbot Medical® to Open Inaugural Endovascular Robotics Session at the Society of Robotic Surgery Annual Meeting
July 8, 2025
Microbot Medical® Added to the Russell Microcap® Index
June 30, 2025
Microbot Medical Strengthens Global IP Portfolio with Newly Granted Patent in China
June 17, 2025
Microbot Medical Continues to Strengthen Commercial Capabilities in Preparation for the anticipated Q3 2025 Launch of its LIBERTY® Endovascular Robotic System
June 9, 2025
Microbot Medical Selected for Preliminary Inclusion to Russell Microcap® Index
June 5, 2025
Microbot Medical® Bolsters Commercial Leadership Team with the Addition of Experienced Healthcare Officers
April 23, 2025
Microbot Medical® Shares Results from Its Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY® Endovascular Robotic System
April 9, 2025
REMINDER: Microbot Medical Announces Data from the Company’s ACCESS-PVI trial will be Presented via Podium Presentation at Society of Interventional Radiology Annual Meeting
April 1, 2025
Microbot Medical Appoints Seasoned Endovascular Sales Executive to Lead its U.S. Sales Activities for LIBERTY® Endovascular Robotic System
March 4, 2025
Robotic Telesurgery Data from Collaboration with Corewell Health™ Accepted for Presentation at the Cardiovascular Research Technologies Annual Meeting
February 25, 2025
Microbot Medical Closes $13 Million Registered Direct Offering
February 10, 2025
Microbot Medical Announces $13 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
February 9, 2025
Microbot Medical® Announces Late-Breaking Abstract Acceptance at the Society of Interventional Radiology Annual Meeting
February 3, 2025
Microbot Medical® Strengthens Its Management Team in Support of the Anticipated Commercial Launch of LIBERTY®
January 20, 2025
Microbot Medical® Strengthens Its Commercial Capabilities with the Addition of David J. Wilson to the Board of Directors
January 12, 2025
Microbot Medical Closes $8.6 Million Registered Direct Offering
January 9, 2025
Microbot Medical Announces $8.6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
January 7, 2025
Microbot Medical Raises a Total of Approximately $11.8 Million in Gross Proceeds from Registered Direct Offering and Previously Announced ATM Facility
January 6, 2025
Microbot Medical Announces $7 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
January 5, 2025
Decks in 2025
- Investor Presentation (September 2025)
Investor deck · 21 slides · Sep 9, 2025
- Investor Presentation (April 2025)
Investor deck · 20 slides · Apr 30, 2025